Idiopathic Pulmonary Fibrosis Clinical Trial
Official title:
Using Xenon MRI to Evaluate the Efficacy of Therapies for Idiopathic Pulmonary Fibrosis
The purpose of this study is being done to determine whether magnetic resonance imaging (MRI) using inhaled hyper-polarized 129 Xenon gas can help visualize impaired lung function to detect changes over time in Idiopathic Pulmonary Fibrosis (IPF) patients receiving approved IPF treatments. Subjects will undergo an approximately hour long comprehensive MRI protocol, including administration of multiple doses of hyper-polarized 129 Xenon. The subjects will have this initial study prior to initiation of IPF therapies. Then the subjects will have repeat studies at 3, 6 and 12 months following the initiation of therapy. Additional studies including pulmonary function studies, serum for bio markers, 6 minute walk distance and a high-resolution computed tomography (HRCT) scan (only at the 6 month visit) will be performed to determine how 129 Xenon MRI performs relative to standard of care evaluations for IPF. The MRI uses a magnet and radio waves to make diagnostic medical images of the body. There have been no ill effects reported from exposure to the magnetism or radio waves used in this test. Risks of the xenon gas are slight numbness in legs, nausea, a feeling of well-being, and mild tingling in fingertips. You will have pulmonary function testing for the study, you may experience breathlessness or dizziness during or immediately following these tests.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT05984992 -
The First-in-human Study of SRN-001 in Healthy Participants
|
Phase 1 | |
| Active, not recruiting |
NCT04312594 -
Study of Jaktinib Hydrochloride Tablets in Participants With Idiopathic Pulmonary Fibrosis
|
Phase 2 | |
| Recruiting |
NCT03865927 -
GKT137831 in IPF Patients With Idiopathic Pulmonary Fibrosis
|
Phase 2 | |
| Completed |
NCT03979430 -
Early Detection of Acute Exacerbation in Patients With Idiopathic Lung Fibrosis - a Pilot Study
|
N/A | |
| Enrolling by invitation |
NCT04905693 -
Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis
|
Phase 3 | |
| Terminated |
NCT04419558 -
Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)
|
Phase 3 | |
| Completed |
NCT03725852 -
A Clinical Study to Test How Effective and Safe GLPG1205 is for Participants With Idiopathic Pulmonary Fibrosis (IPF)
|
Phase 2 | |
| Terminated |
NCT03573505 -
An Efficacy and Safety Study of BG00011 in Participants With Idiopathic Pulmonary Fibrosis
|
Phase 2 | |
| Recruiting |
NCT04148157 -
Quality of Life in IPF - Patient and Physician Perceptions
|
||
| Completed |
NCT03222648 -
Structured Exercise Training Programme in Idiopathic Pulmonary Fibrosis
|
N/A | |
| Completed |
NCT02257177 -
RCT (Randomized Control Trial) of TD139 vs Placebo in HV's (Human Volunteers) and IPF Patients
|
Phase 1/Phase 2 | |
| Completed |
NCT02268981 -
Effects of an Oxymizer® During Daytime in Patients With Pulmonary Fibrosis (IPF)
|
N/A | |
| Withdrawn |
NCT01524068 -
A MultiCenter Study of Combined PEX, Rituximab, and Steroids in Acute Idiopathic Pulmonary Fibrosis Exacerbations
|
Phase 2 | |
| Enrolling by invitation |
NCT01382368 -
Acute Effect of Sildenafil on Exercise Tolerance and Functional Capacity in COPD, IPF and Post Pneumonectomy Patients
|
Phase 4 | |
| Completed |
NCT01199887 -
Trial Of IW001 in Patients With Idiopathic Pulmonary Fibrosis
|
Phase 1 | |
| Completed |
NCT01110694 -
Prospective Observation of Fibrosis in the Lung Clinical Endpoints Study
|
||
| Active, not recruiting |
NCT02951416 -
Clinical Course of Interstitial Lung Diseases: European IPF Registry and Biobank
|
||
| Terminated |
NCT00981747 -
Targeting Vascular Reactivity in Idiopathic Pulmonary Fibrosis
|
Phase 2/Phase 3 | |
| Completed |
NCT00540475 -
Pennsylvania Idiopathic Pulmonary Fibrosis Research Registry
|
||
| Completed |
NCT00532233 -
SD, IL-13 Production Rate in IPF
|
Phase 2 |